Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$542K Buy
3,822
+2,049
+116% +$329K ﹤0.01% 4034
2026
Q2
$299K Buy
+1,773
New +$263K ﹤0.01% 3178
2026
Q1
– Sell
-90,325
Closed -$12.8M – 4765
2025
Q4
$12.8M Buy
90,325
+67,719
+300% +$9.8M 0.04% 496
2025
Q3
$3.17M Sell
22,606
-4,894
-18% -$663K 0.01% 1230
2025
Q2
$3.46M Sell
27,500
-51,196
-65% -$5.87M 0.01% 1116
2025
Q1
$8.7M Buy
78,696
+69,737
+778% +$8.83M 0.04% 499
2024
Q4
$1.22M Sell
8,959
-79,187
-90% -$9.8M ﹤0.01% 2201
2024
Q3
$10.2M Buy
88,146
+83,559
+1,822% +$11.5M 0.02% 687
2024
Q2
$631K Buy
4,587
+4,037
+734% +$554K ﹤0.01% 3299
2024
Q1
$75.9K Buy
+550
New +$75.1K ﹤0.01% 4523
2023
Q4
– Sell
-30,713
Closed -$3.46M – 5323
2023
Q3
$3.46M Buy
+30,713
New +$3.23M 0.01% 1313
2023
Q2
– Sell
-15,161
Closed -$1.53M – 4690
2023
Q1
$1.53M Buy
+15,161
New +$1.58M 0.02% 877
2022
Q2
– Sell
-25,533
Closed -$2.39M – 2597
2022
Q1
$2.39M Sell
25,533
-2,849
-10% -$241K 0.06% 322
2021
Q4
$2.42M Buy
28,382
+24,582
+647% +$2.26M 0.08% 288
2021
Q3
$364K Sell
3,800
-4,187
-52% -$395K 0.01% 929
2021
Q2
$777K Buy
+7,987
New +$766K 0.03% 549
2020
Q2
– Sell
-1,734
Closed -$150K – 845
2020
Q1
$150K Sell
1,734
-7,094
-80% -$694K 0.03% 505
2019
Q4
$949K Buy
8,828
+6,191
+235% +$648K 0.06% 439
2019
Q3
$238K Buy
+2,637
New +$246K 0.01% 1112

Other funds holding NBIX

Walleye Capital's NBIX Position: Q3 2026 in Review

Walleye Capital increased its Neurocrine Biosciences (NBIX) stake by 116% in Q3 2026, buying an estimated $329K and bringing the position to 3,822 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #4034.

Walleye Capital first reported a position in NBIX in Q3 2019 and has held it in 19 quarters since. The position peaked at $12.8M in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Walleye Capital held 3,822 shares of Neurocrine Biosciences worth $542K as of Q3 2026.
  • Walleye Capital bought 2,049 Neurocrine Biosciences shares in Q3 2026, an estimated $329K.
  • Neurocrine Biosciences made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4034 holding.
  • Walleye Capital first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 19 quarters since.
  • Walleye Capital's Neurocrine Biosciences position peaked at $12.8M in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.